Coagulopathy, broadly defined as a disorder of blood clotting, may result from inherited conditions, acquired diseases, medications, or systemic disturbances. Regardless of its cause, impaired hemostasis significantly increases the risk of perioperative bleeding, transfusion requirements, and postoperative complications. Consequently, perioperative care for patients with coagulopathy requires careful planning, interdisciplinary coordination, and comprehensive monitoring.
Coagulopathies may be congenital, such as hemophilia A, hemophilia B, or von Willebrand disease, or acquired through conditions like liver disease, disseminated intravascular coagulation, or the use of anticoagulant medications. Each etiology presents distinct pathophysiological mechanisms and clinical implications. For example, liver dysfunction affects multiple coagulation factors and platelet function, while anticoagulants such as warfarin or direct oral anticoagulants selectively interfere with specific points in the coagulation cascade. Understanding the underlying defect causing coagulopathy in the individual patient is necessary for proper perioperative management.
Laboratory evaluation in the preoperative period is necessary and may include complete blood count, prothrombin time, activated partial thromboplastin time, fibrinogen levels, and specific factor assays when indicated. In certain complex cases, viscoelastic testing may provide a dynamic assessment of clot formation and stability. Laboratory results must be interpreted in the context of clinical findings, as abnormal values do not always correlate directly with bleeding risk.
Optimization before surgery involves correcting reversible abnormalities where possible. For patients with vitamin K deficiency or warfarin-associated coagulopathy, vitamin K administration may restore clotting factor synthesis. In more urgent settings, prothrombin complex concentrates or fresh frozen plasma may be required for rapid reversal. Individuals with hemophilia may need targeted replacement of deficient clotting factors, while those with von Willebrand disease may benefit from desmopressin or von Willebrand factor concentrates. In thrombocytopenic patients, platelet transfusion may be necessary, depending on the anticipated invasiveness of the procedure and the platelet count threshold that is deemed safe.
Intraoperative management of coagulopathy should focus on minimizing blood loss and maintaining hemodynamic stability. Careful surgical technique helps by minimizing tissue trauma and guiding appropriate use of electrocautery or topical hemostatic agents, which can significantly reduce bleeding. Anesthetic considerations also matter. Avoiding hypothermia, acidosis, and hypocalcemia is vital, as these conditions impair coagulation.
Real-time monitoring of blood loss and coagulation parameters guides transfusion decisions and helps prevent both under- and over-correction. Excessive transfusion carries its own risks, including transfusion reactions, volume overload, and immunologic complications.
Postoperatively, early identification of bleeding, whether external or internal, allows prompt intervention. Monitoring drains, wound sites, hemoglobin levels, and vital signs provides insights into patients’ statuses. Resumption of anticoagulation therapy, when indicated, requires careful timing to balance the risk of thrombosis against postoperative bleeding. In some patients, mechanical thromboprophylaxis may be used temporarily until pharmacologic agents can be safely restarted.
Effective perioperative care for patients with coagulopathy depends on collaboration among surgeons, anesthesiologists, hematologists, and nursing staff. Clear communication, standardized protocols, and individualized treatment plans reduce complications and improve outcomes. While the presence of a bleeding disorder increases surgical risk, modern diagnostic tools, targeted therapies, and refined perioperative strategies have substantially enhanced safety.